Description:
A drug used to treat adults and children aged 1 month and older with certain types of B-cell acute lymphoblastic leukemia that are CD19 positive (expresses the protein CD19). It is also being studied in the treatment of other types of cancer. Blincyto binds to CD19, which is found on most B cells (a type of white blood cell) and some types of leukemia cells. It also binds to a protein called CD3, which is found on T cells (another type of white blood cell). This may help the immune system kill cancer cells. Blincyto is a type of bispecific T-cell engager. Also called blinatumomab.
